bpc 157 human dosing bpc-157 clinical trial dose microgram Frontiers BPC-157 (Common Protocols), 🔹 – BPC-157 Dosage Protocol: Injection Guide

Within those categories, the clinical picture is clearer than the internet makes it seem

The retraction issue

The wrist presents several suitable subcutaneous injection sites depending on the condition being addressed

In terms of completion of the entire trial, 29 participants were treated with a combined treatment of cagrilintide and semaglutide and treatment with semaglutide by itslef while 30 participants were treated with cagrilintide

2014 follow-up study was retracted in 2025, which means the foundational evidence base has significant integrity concerns that should be weighed carefully

Hence, BPC-157 is clearly on the do not compound for human use list